Print Page   |   Contact Us   |   Sign In   |   Join iBIO
Industry News

TOP industry news from Business Wire

Fabric Genomics gaat samenwerken met Europese serverprovider ITTM voor het leveren van veilige genoomanalyse in EuropaOpen in a New Window

OAKLAND, Californië en BOSTON en KOPENHAGEN, Denemarken--(BUSINESS WIRE)--Fabric Genomics, een wereldwijd rekenkundig genomicabedrijf dat data-analyse en klinische rapportagetools aanbiedt, heeft vandaag aangekondigd dat het gaat samenwerken met het datamanagementbedrijf ITTM S.A. (Information Technology for Translational Medicine) voor het leveren van veilige genomische data hostingmogelijkheden voor Europese klanten. Door het combineren van de toonaangevende analysetools van Fabric Genomics m


Panaceutics CEO to Speak at Precision Medicine World ConferenceOpen in a New Window

DURHAM, N.C.--(BUSINESS WIRE)--#PWMC--Precision medicine is expected to change the way medicine is prescribed to patients and improve patient adherence. Experts gathered at Duke to pave the new path.


QuintilesIMS Announces Launch of Secondary Public Offering, Repurchase of Common Stock and Increase in Share Buyback AuthorizationOpen in a New Window

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Quintiles IMS Holdings, Inc. (“QuintilesIMS”) (NYSE: Q) announced today the launch of an underwritten, secondary public offering of 10,571,003 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC, CPP Investment Board Private Holdings, Inc., investment funds associated with Bain Capital Investors, LLC, Leonard Green & Partners, L.P., and Dr. Dennis B. Gillings, CBE and cert


De nouvelles données issues de deux essais cliniques randomisés multicentriques démontrent que les valves endobronchiques Zephyr offrent des avantages aux patients atteints d'emphysèmes homogènes et homogènes sans ventilation collatéraleOpen in a New Window

WASHINGTON et REDWOOD CITY, Californie--(BUSINESS WIRE)--Pulmonx®, Inc. a annoncé aujourd'hui les résultats de deux essais cliniques multicentriques et randomisés montrant des améliorations cliniquement significatives de la fonction pulmonaire après traitement avec les valves endobronchiques Zephyr® (VEB) chez des patients atteints d'emphysème sans ventilation collatérale. Les données à six mois des essais TRANSFORM et IMPACT, présentées cette semaine à l'occasion de la conférence international


Antibe Therapeutics Inc. Announces Proposed Offering of UnitsOpen in a New Window



Fabric Genomics instaura una collaborazione con il fornitore di server europeo ITTM per l'offerta di soluzioni per la conduzione di analisi genomiche sicure in EuropaOpen in a New Window

OAKLAND, California, BOSTON e COPENHAGEN, Danimarca--(BUSINESS WIRE)--Fabric Genomics, una società di portata globale operante nel ramo della genomica computazionale impegnata nell'offerta di strumenti per l'analisi di dati e la reportistica clinica, ha annunciato in data odierna di aver instaurato una collaborazione con la società specializzata nella gestione di dati ITTM S.A. (Information Technology for Translational Medicine) per l'offerta di capacità di hosting di dati genomici ai clienti n


Puma Biotechnology Receives FDA Advisory Committee Support for NeratinibOpen in a New Window

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology Receives ODAC Support for Neratinib


Gecko Biomedical Appoints Youssef Biadillah as Chief Development Officer. Maria Pereira Transitions to Chief Innovation Officer.Open in a New Window

PARIS--(BUSINESS WIRE)--Gecko Biomedical appoints Youssef Biadillah as Chief Development Officer. Maria Pereira transitions to Chief Innovation Officer.


Neural Analytics Announces Data that Demonstrates its Portable Transcranial Doppler Technology Can Assess Early Strokes With More than 95 Percent AccuracyOpen in a New Window

LOS ANGELES--(BUSINESS WIRE)--Neural Analytics announces data that demonstrates its portable transcranial Doppler technology can assess early strokes with more than 95 percent accuracy.


U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) in Previously Treated Hepatocellular CarcinomaOpen in a New Window

PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #ASCO17--U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) in Previously Treated Hepatocellular Carcinoma


Colorado BioScience Association Appoints New Board LeadershipOpen in a New Window

DENVER--(BUSINESS WIRE)--Colorado BioScience Association announces new board members. Scott Larson, Terumo BCT General Counsel, named chairman of the board.


Concert Pharmaceuticals Announces Shareholder Approval of CTP-656 Asset Purchase Agreement with Vertex PharmaceuticalsOpen in a New Window

LEXINGTON, Mass.--(BUSINESS WIRE)--$CNCE #CNCE--Concert shareholders voted to approve the asset purchase agreement under which Vertex Pharmaceuticals will acquire CTP-656 for the treatment of cystic fibrosis.


Samenvatting: Nieuwe resultaten van twee gerandomiseerde, klinische multi-centeronderzoeken bewijzen dat Zephyr Endobronchial Valves positief effect hebben op patiënten met heterogeen of homogeen emfyseem zonder collaterale ventilatieOpen in a New Window

WASHINGTON & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx®, Inc. maakt vandaag de resultaten bekend van twee gerandomiseerde, in meerdere centra uitgevoerde, klinisch-wetenschappelijke onderzoeken die bewijs leveren voor klinisch relevante verbeteringen van de longfunctie bij patiënten met longemfyseem zonder collaterale ventilatie die zijn behandeld met de Zephyr® Endobronchial Valve. De onderzoeksresultaten na zes maanden van zowel TRANSFORM als IMPACT, die deze week zijn gepresenteerd op d


Resumen: Nuevos datos de dos estudios clínicos aleatorios multicentro demuestran que las válvulas endobroquiales Zephyr son beneficiosas para pacientes con enfisema heterogéneo y homogéneo con ventilación colateralOpen in a New Window

WASHINGTON & REDWOOD CITY, California--(BUSINESS WIRE)--Pulmonx®, Inc. ha anunciado los resultados de dos estudios clínicos aleatorios, multicentro que desvelan mejoras clínicamente notables en la función pulmonar tras el tratamiento con la válvula endobronquial Zephyr® (EBV) en pacientes con enfisema sin ventilación colateral. Los datos de seis meses de los ensayos TRANSFORM e IMPACT, presentados esta semana en el congreso internacional de la American Thoracic Society, demuestran que las válvu


ProtoKinetix Completes First Year of Trials on Retinal Replacement Therapy Using AAGP™Open in a New Window

ST. MARYS, W. Va.--(BUSINESS WIRE)--ProtoKinetix Completes First Year of Trials on Retinal Replacement Therapy Using AAGP™


BIO Applauds Creation of FDA Opioid Policy Steering CommitteeOpen in a New Window

WASHINGTON--(BUSINESS WIRE)--Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued a statement today regarding the announced creation of an Opioid Policy Steering Committee at the FDA.


Global Bone Graft and Substitute Market (2017-2023) - Segmented by Type, Application & Region - Research and MarketsOpen in a New Window

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Bone Graft and Substitute Market Insights, Opportunity, Analysis, Market Shares And Forecast 2017 - 2023" report to their offering. The global bone graft and substitutes market is anticipated to grow at a CAGR of 4.7% during 2016 to 2023. Bones have the usual capability to rebuild, but the surgical intervention is required to regenerate the bone if the defects exceed a critical size. The healing of fractures


Alnylam Pharmaceuticals Prices Public Offering of Common StockOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $71.87 per share. The gross proceeds to Alnylam from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $359.4 million. The offering is expected to clo


Biologics’ Patient Access Services Team Procures More Than $44 Million in Co-Pay Assistance for Cancer Patients in 2016Open in a New Window

CARY, N.C.--(BUSINESS WIRE)--Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, secured more than $44 million in co-pay assistance in 2016 for commercial patients in need of oral chemotherapy drugs.


Acelity Launches PREVENA DUO™ Incision Management System Platform – the First Single-Use Negative Pressure Wound Therapy (NPWT) System for the Simultaneous Management of Two IncisionsOpen in a New Window

SAN ANTONIO--(BUSINESS WIRE)--Acelity Launches PREVENA DUO™ Incision Management System Platform – the First Single-Use Negative Pressure Wound Therapy (NPWT) System for the Simultaneous Management of Two Incisions


Liquidia Technologies Announces Positive Phase 1 Data for LIQ865, Sustained-Delivery PRINT® Formulation of Bupivacaine for Post-Surgical Pain ReliefOpen in a New Window

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Liquidia Technologies, Inc., today announced initial data from its LIQ865 internal clinical development program, which is a PRINT® formulation for the sustained-delivery of free base bupivacaine for post-surgical pain relief. The phase 1 trial, marking the first evaluation of LIQ865 in humans, was a randomized, controlled, double-blind study evaluating the safety, pharmacokinetic profile and pharmacodynamic response of a single-ascending dose in he


ImmunoGen Announces Webcast of Presentation at the Jefferies Global Healthcare ConferenceOpen in a New Window

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation at the Jefferies Global Healthcare Conference


L'Université d'État du Colorado et Synaptive Medical travaillent ensemble pour mieux détecter les tumeurs cérébralesOpen in a New Window

FORT COLLINS, Colorado--(BUSINESS WIRE)--Le Flint Animal Cancer Center de l'Université d'État du Colorado (CSU) et Synaptive Medical Inc. collaborent pour développer une technologie d'imagerie et de détection peropératoire pour détecter et traiter les tumeurs cérébrales de manière plus précise. Le Dr Rebecca Packer, professeure associée de neurologie et de neurochirurgie à l'Université d'État du Colorado, est la première neurochirurgienne au monde à utiliser le système Raman de recherche par sp


NovaBone Announces Irrigation Resistant Products with Carriers that have Synergistic Effect in Bone FormationOpen in a New Window

JACKSONVILLE, Fla.--(BUSINESS WIRE)--The IRM™ series has been designed to optimize osteogenesis while providing exceptional handling properties, including irrigation resistance.


ドンペが中等度および重度の成人神経栄養性角膜炎患者の治療薬としてのOxervate®(Cenegermin点眼薬)に対するCHMPの肯定的意見を欧州で受領Open in a New Window

ミラノ--(BUSINESS WIRE)--(ビジネスワイヤ) -- バイオ医薬品企業のドンペは本日、欧州医薬品庁(EMA)の医薬品評価委員会(CHMP)が、中等度および重度の成人神経栄養性角膜炎患者の治療薬としてOxervate®(cenegermin点眼薬)の市販承認を推奨する肯定的意見を発出したと発表しました。神経栄養性角膜炎は障害をもたらす希少な眼疾患で、視力低下につながる場合があります。現時点ではこの疾患に対する満足のいく治療法は存在しません。CHMPは本病状に伴うリスクと、実現可能な治療選択肢が欠如していることを理由に、迅速審査制度を通じた審査を完了しました。審査は2016年11月に開始し、肯定的意見を採択して先週完了しました。 神経栄養性角膜炎の原因は、三叉神経(眼の解剖学的構造と機能を担う神経の1つ)の障害と関連しており、この障害は角膜知覚の喪失をもたらす場合があります。最重症型では角膜の潰瘍・融解・穿孔の原因となり、患者の視認能力を損ねるおそれがあります2。 EMAの希少疾病用医薬品委員会(COMP)が確認して欧州委員会が承認した場合、Oxervate®は本適応症で


Recro Gainesville Expands Manufacturing Capabilities with New Tableting Equipment and Growing Development TeamOpen in a New Window

GAINESVILLE, Ga.--(BUSINESS WIRE)--Recro Gainesville, LLC has expanded its capabilities by adding a new tablet manufacturing suite and growing its development team.


Trinity Partners to Present and Release New Whitepaper at ISPOR Annual MeetingOpen in a New Window

BOSTON--(BUSINESS WIRE)--Trinity Partners, a global life sciences consulting firm, announced today that it will participate in the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting, being held in Boston on May 20-24. This year’s ISPOR meeting draws healthcare stakeholders with an interest in health economics and outcomes research (HEOR), including policy makers, payers, thought leaders, researchers, academicians, decision makers and pati


California Life Sciences Association Statement on President’s 2018 Budget RequestOpen in a New Window

SAN FRANCISCO & SAN DIEGO--(BUSINESS WIRE)--California Life Sciences Association Statement on President’s 2018 Budget Request


GlycoMimetics Announces Pricing of Public Offering of Common StockOpen in a New Window

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (NASDAQ: GLYC), a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced the pricing of its underwritten public offering of 7,000,000 shares of its common stock at a price to the public of $11.50 per share. The gross proceeds from the offering are expected to be $80.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by G


Fabric Genomics Partners with European Server Provider ITTM to Deliver Secure Genomic Analysis in EuropeOpen in a New Window

OAKLAND, Calif. & BOSTON & COPENHAGEN, Denmark--(BUSINESS WIRE)--Fabric Genomics, a global computational genomics company offering data analysis and clinical reporting tools, announced today that it has partnered with data management company ITTM S.A.


IPF patients treated with OFEV® (nintedanib) versus placebo were twice as likely to have improved or stable lung function1Open in a New Window

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced the presentation of new analyses on the use of OFEV® (nintedanib) in treating idiopathic pulmonary fibrosis (IPF) at the 2017 American Thoracic Society (ATS) conference. Abstracts presented at the conference support the established efficacy and safety data for OFEV®, and offer further insights into its effect on lung function in IPF patients. Pooled data from the two Phase III INPULSIS® trials showed that OFEV®-treated pa


Akebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease Hyporesponsive to Treatment with Erythropoiesis-Stimulating AgentsOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that the Company dosed the first patient in its Phase 2 FO2RWARD study of vadadustat in dialysis-dependent chronic kidney disease (DD-CKD) patients who are hyporesponsive to erythropoiesis-stimulating agents (ESAs). Vadadustat is an oral HIF stabili


CEL-SCI Corporation Releases Letter to ShareholdersOpen in a New Window

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation releases letter to shareholders.


SCIEX Announces the First FDA-Cleared Vitamin D Assay Kit for Mass SpectrometryOpen in a New Window

FRAMINGHAM, Mass.--(BUSINESS WIRE)--SCIEX Diagnostics announced today the first and only FDA-cleared (via the de novo pathway) LC-MS based Vitamin D assay kit, the Vitamin D 200M Assay, exclusively for the SCIEX Topaz System.


Resumen: JSR Life Sciences amplía capacidades de fabricación en KBI BiopharmaOpen in a New Window

DURHAM, Carolina del Norte--(BUSINESS WIRE)--JSR Life Sciences (JLS) ha anunciado que KBI Biopharma (KBI), una filial de JSR Corporation (JSR), ha ampliado sus capacidades de fabricación biofarmacéuticas en sus instalaciones de Durham (Carolina del Norte) y Boulder (Colorado). KBI ha invertido aproximadamente $30 millones en dos proyectos de expansión en las dos fábricas, lo que mejorará considerablemente las ofertas en cada sitio y que se completarán a finales de año. KBI ha creado una capacid


GORE® EXCLUDER® Iliac Branch Endoprosthesis Approved in JapanOpen in a New Window

FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) announced the first implants in Japan of the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE). Gore has received Shonin approval from the Japanese Ministry of Health, Labour and Welfare to market the IBE and is currently in discussion regarding reimbursement for this region. The IBE is the first off-the-shelf iliac branch solution approved in Japan and the only device indicated for the endovascular treatment of common


Riffyn Named a 2017 “Cool Vendor” by GartnerOpen in a New Window

OAKLAND, Calif.--(BUSINESS WIRE)--#reproducibility--Riffyn Named "Cool Vendor" by Gartner for R&D Manufacturing.


Innovus Pharma Launches AllerVarx, a Clinically Proven Supplement for the Relief of Allergy Symptoms, in the United StatesOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced the launch of AllerVarx™ in the U.S. AllerVarx™ is a clinically proven supplement, scientifically formulated for the relief of allergy symptoms. “L


Samenvatting: JSR Life Sciences breidt productiecapaciteit KBI Biopharma uitOpen in a New Window

DURHAM, N.C.--(BUSINESS WIRE)--JSR Life Sciences (JLS) heeft vandaag aangekondigd dat KBI Biopharma (KBI), dochteronderneming van JSR Corporation (JSR), zijn biofarmaceutische productiecapaciteiten van zijn faciliteiten in Durham, North Carolina, en Boulder, in Colorado, uitbreidt. KBI investeert circa 30 miljoen dollar in de twee uitbreidingen, die het aanbod per locatie aanzienlijk versterken. De uitbreidingswerkzaamheden zijn volgens planning later dit jaar afgerond. KBI bouwt installaties v


Bacterial Biofilm Infections: Personalizing Patient Treatment Using xCELLigence AssaysOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--#novocyte--Bacterial biofilms, surface adherent communities of bacteria that are encased in a secreted extracellular matrix of polymeric molecules, can cause diverse pathologies ranging from food poisoning and catheter infections to gum disease and the rejection of medical implants. Though the economic impact of biofilms is in the tens of billions of dollars per year, there is currently a paucity of means for preventing their formation or treating them once they are established


ICON and Regeneron Win Best Partnership in Clinical Research Award from PharmaTimesOpen in a New Window

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, and Regeneron Pharmaceuticals, Inc., a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions, have won the Partnership in Clinical Research award at the 2017 PharmaTimes International Clinical Research


$3.51 Billion Cell Signaling Market by Type, Pathway, Product, Technology & Application - Global Forecast to 2022 - Research and MarketsOpen in a New Window

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Cell Signaling Market by Type, Pathway, Product, Technology & Application - Global Forecast to 2022" report to their offering. The cell signaling market is expected to reach USD 3.51 billion by 2022 from USD 2.53 billion in 2017, at a CAGR of 6.8% Factors such as increasing incidence of various chronic diseases; rising funding for cell-based research activities; introduction of innovative and advanced instrumen


Neue Studiendaten unterstreichen gesundheitliche Verbesserungen durch EndobronchialventileOpen in a New Window

FREISING, Deutschland--(BUSINESS WIRE)--Pulmonx®, Inc. gab heute die Ergebnisse von zwei multizentrischen, randomisierten klinischen Studien bekannt, die klinisch signifikante Verbesserungen in der Lungenfunktion bei Lungenemphysem-Patienten ohne Kollateralventilation nach der Behandlung mit dem Zephyr®-Endobronchialventil (EBV) aufzeigen. 6-Monats-Daten aus den TRANSFORM- und IMPACT-Studien, die diese Woche auf der internationalen Konferenz der American Thoracic Society (ATS) in Washington, D.


JSR Life Sciences erweitert Fertigungskapazitäten bei KBI BiopharmaOpen in a New Window

DURHAM, North Carolina (USA)--(BUSINESS WIRE)--JSR Life Sciences (JLS) gab heute bekannt, dass KBI Biopharma (KBI), eine Tochtergesellschaft der JSR Corporation (JSR), die Fertigungskapazitäten und -möglichkeiten ihrer Anlagen in Durham, North Carolina und Boulder, Colorado, erweitert. KBI investiert rund 30 Mio. US-Dollar in zwei Standort-Expansionsprojekte. Damit sollen die Angebote an jedem Standort jeweils deutlich verbessert werden. Der Abschluss der Projekte ist für später im Jahr geplant


JSR Life Sciences étend ses capacités de fabrication à KBI BiopharmaOpen in a New Window

DURHAM, Caroline du Nord--(BUSINESS WIRE)--JSR Life Sciences (JLS) a annoncé aujourd'hui que KBI Biopharma (KBI), une filiale de JSR Corporation (JSR), avait décidé d'élargir ses capacités de fabrication biopharmaceutique au niveau de son site de Durham, en Caroline du Nord, et de son site de Boulder, dans le Colorado. KBI investit actuellement environ 30 millions USD pour ses deux projets d'expansion des sites, ce qui permettra d'améliorer considérablement les offres de chaque site. Les travau


Pierre Fabre Pharmaceuticals Acquires Promising Assets from Igenica Biotherapeutics in the Field of Immuno-OncologyOpen in a New Window

CASTRES, France--(BUSINESS WIRE)--Pierre Fabre, the 2nd largest French private Pharmaceutical group, today announced the signature of a definitive purchase agreement to acquire several assets from the biotechnology company Igenica Biotherapeutics, based in Burlingame, California, USA. The agreement includes innovative immunotherapies targeting immune checkpoints that may reverse the resistance to existing immuno therapies. The most advanced asset is currently at preclinical stage and is expecte


Pierre Fabre Pharmaceuticals rileva da Igenica Biotherapeutics degli asset promettenti nel settore immuno-oncologicoOpen in a New Window

CASTRES, Francia--(BUSINESS WIRE)--Pierre Fabre, il secondo gruppo farmaceutico privato francese, ha oggi annunciato la conclusione di un accordo d'acquisto definitivo relativo a diversi asset della società biotecnologica Igenica Biotherapeutics, con sede a Burlingame, in California (Stati Uniti). L'accordo riguarda innovative immunoterapie mirate a checkpoint immunologici potenzialmente in grado di modificare in senso positivo la resistenza alle immunoterapie correntemente utilizzate. L'asset


Pierre Fabre Pharmaceuticals übernimmt viel versprechende Assets von Igenica Biotherapeutics auf dem Gebiet der Immun-OnkologieOpen in a New Window

CASTRES, Frankreich--(BUSINESS WIRE)--Pierre Fabre, die zweitgrößte französische private Pharmagesellschaft, meldete heute die Unterzeichnung einer definitiven Kaufvereinbarung für die Übernahme des Biotechnologieunternehmens Igenica Biotherapeutics mit Sitz in Burlingame im US-Bundesstaat Kalifornien. Der Vertrag umfasst innovative, auf Immuncheckpoints gerichtete Immuntherapien, die in der Lage sind, die Resistenz gegenüber bestehenden Immuntherapien aufzuheben. Der fortgeschrittenste Asset b


Pierre Fabre Pharmaceuticals adquiere importantes activos de Igenica Biotherapeutics en el campo de la inmuno-oncologíaOpen in a New Window

CASTRES, France--(BUSINESS WIRE)--Pierre Fabre, el segundo mayor grupo farmacéutico privado francés, ha anunciado la firma de un acuerdo definitivo para la adquisición de varios activos de la empresa biotecnológica Igenica Biotherapeutics, con sede en Burlingame, California (EE. UU.). El acuerdo incluye innovadoras inmunoterapias dirigidas a puntos de control inmunológicos que puedan revertir la resistencia a las inmunoterapias existentes. El activo más avanzado se encuentra en la actualidad en


Pierre Fabre Pharmaceuticals verwerft veelbelovende activa van Igenica Biotherapeutics op het gebied van immuno-oncologieOpen in a New Window

CASTRES, Frankrijk--(BUSINESS WIRE)--Pierre Fabre, de op één na grootste Franse particuliere farmaceutische groep, heeft vandaag de ondertekening van een definitieve koopovereenkomst aangekondigd om diverse activa te verwerven van het biotechnologisch bedrijf Igenica Biotherapeutics, gevestigd in Burlingame, Californië, Verenigde Staten. De overeenkomst omvat innovatieve immunotherapieën die gericht zijn op immuniteitscontrolepunten die de resistentie tegen bestaande immunotherapieën kunnen ker


Pierre Fabre Médicament rachète des actifs prometteurs à Igenica Biotherapeutics dans le domaine de l’immuno-oncologieOpen in a New Window

CASTRES, France--(BUSINESS WIRE)--Pierre Fabre, 2ème groupe pharmaceutique privé français, a annoncé aujourd'hui la signature d’un accord définitif d'achat portant sur plusieurs actifs de la société de biotechnologie Igenica Biotherapeutics, basée à Burlingame en Californie (États-Unis). L’accord inclut des immunothérapies innovantes inhibitrices de « checkpoint » susceptibles de réduire la résistance aux immunothérapies existantes. L’actif le plus avancé est actuellement au stade préclinique e


Lysogene Selects Brammer Bio to Produce GM1 Gangliosidosis Gene Therapy ProductOpen in a New Window

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: Lysogene (Paris:LYS) (FR0013233475 – LYS), a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced that it has entered into a strategic manufacturing agreement with Brammer Bio, a best-in-class viral gene and cell therapy manufacturer. Brammer Bio will produce LYS-GM101, an AAVrh10-based gene therapy, for clinical testing of the therapeutic candidate in patient


Lysogene choisit Brammer Bio pour fabriquer son produit de thérapie génique pour la Gangliosidose à GM1Open in a New Window

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: Lysogene, (Paris:LYS) (la « Société » FR0013233475 – LYS) société biopharmaceutique spécialisée dans la thérapie génique ciblant les maladies du système nerveux central (SNC), annonce aujourd’hui la signature d’un accord stratégique de fabrication avec Brammer Bio, l’un des principaux fabricants de produits de thérapie cellulaire et génique par vecteur viral. Brammer Bio fabriquera LYS-GM101, le second candidat-médicament de Lysogene u


Biogen’s FAMPYRA® Granted Standard Marketing Authorization in European Union for Improvement of Walking in People with MSOpen in a New Window

ZUG, Switzerland--(BUSINESS WIRE)--Biogen’s FAMPYRA® Granted Standard Marketing Authorization in European Union for Improvement of Walking in People with MS


OurCrowd Invests $2.5 Million in Scopio Labs, Brings Total to $80 Million Invested in Healthcare CompaniesOpen in a New Window

JERUSALEM--(BUSINESS WIRE)--OurCrowd, a global leader in equity crowdfunding, today announced that it will invest $2.5 million (as part of a recently completed $7 million investment round) in Scopio Labs, a developer of an advanced digital microscopy and diagnostics platform. This is OurCrowd’s 23rd healthtech investment for a total of $80 million, making OurCrowd the world’s leading equity crowdfunding platform for healthcare investments. OurCrowd CEO Jon Medved said, “We are excited by our la
Association Management Software Powered by YourMembership  ::  Legal